The gene encoding the short PFK1 fragment was tested in several commercial microorganisms. This was done as a part of the EU ANTICO, financed by the European Commission coordinated by prof. Legiša. Partners from Glasgow in Scotland, Graz Austria, Thessaloniki Greece, Lek-Sandoz Slovenia and a small enterprise company from Glasgow in Scotland participated in the project. The industrial use of the modified gene was protected by two patent applications (WO2005/023854, WO2007123498).
F.32 International patent
COBISS.SI-ID: 3165210We invented, based on the analysis of MD-2 tertiary structure model, a new type of covalent inhibitors. The invention was protected by the patent application: Compounds for covalent binding of MD-2 and action on immune responses: PCT WO/2007/030083, in procedure for granting the US patent. Herein we protected the compounds that inhibit TLR4 signalling via formation of a covalent bond with the unique free SH- group of MD-2 (Cys133). Patent protects compounds is that contain a thiol recative group and a segment for binding into the hydrophobic pocket of MD-2.
F.32 International patent
COBISS.SI-ID: 3824922Researchers of the program group organized and mentored a student team from the University of Ljubljana, which in the years 2006 and 2007 successfully completed two research projects. In 2006 our team was a finalist and won the “Grand Prize” award at the international competition in Synthetic biology iGEM2006 held at the elite university MIT in Cambridge, MA, USA. In 2007, our project was again among the six finalists and won the gold medal and the first place among the projects in the field of Medicine and Health. In 2006 33 teams participated and 56 teams in 2007.
E.02 International awards
COBISS.SI-ID: 3853594Researchers of the programme group contributed to build up the 5th FP European project consortium ANEPID (Antimicrobial and Endotoxin Neutralizing Peptides) which was aimed at development of antimicrobial compounds based on the peptide fragment of human lactoferrin. We developed several generations of peptides and lipopeptides showing substantially improved antimicrobial activity compared to the initial peptides. Results were protected in a patent on antimicrobial lipopeptides (WO 2008/006125 A1).
F.32 International patent
COBISS.SI-ID: 3857946We developed a new generation of thermostable monoclonal antibodies for the determination of antigens of the blood group system AB0 in a gel card in cooperation with companies DiaMed from Switzerland and DiaMed Eurogen from Belgium, which put the research achievements into final products. The achievement will enable the use of the standardised test also in the Third World where there is a problem of reagent storage at low temperatures and where a robust but sensitive test is needed. Antibodies against human PrP were protected by an EU patent (EP1158003) and a US patent (US 7098317 B1.
F.32 International patent
COBISS.SI-ID: 2834202